SCRI-E2CAR_EGFRtv1

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSCRI-E2CAR_EGFRtv1
Drug Alias NameAutologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)SCRI-E2CAR_EGFRtv1
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsT-cell surface antigen CD4 modulatorsCluster of differentiation 8 modulators
TargetsT-cell surface antigen CD4Cluster of differentiation 8
Therapy Area/IndicationsOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUmoja BioPharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesUmoja BioPharma Inc
Inactive CompaniesN/A
Active IndicationsOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A